Maureen Newman,  —

Maureen Newman is a senior Science and Research writer for Cystic Fibrosis News Today. Maureen is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

Articles by Maureen Newman

Arcturus Presents mRNA Delivery Data Applicable to CF Treatment

Arcturus Therapeutics, Inc. recently presented encouraging non-human primate studies concerning its preclinical messenger RNA therapies for the potential treatment of genetic diseases such as cystic fibrosis at the 2nd International mRNA Health Conference held November 11-12 in Cambridge, Massachusetts. Arcturus’ presentation, “Potent Delivery of LUNAR™ Nanoparticles Containing Synthetic mRNA for…

New Combination Therapy May Treat 90% of All CF Patients

New ways of treating cystic fibrosis are under development at the University of Dundee. Along with colleagues in Italy, France, and Scotland, Dr. Anil Mehta, a clinical researcher at Dundee’s Medical Research Institute, pioneered a new drug combination that gives hope to patients with cystic fibrosis. “This work shows…

OrPro Presents ORP-100 Results at Cystic Fibrosis Conference

OrPro Therapeutics, Inc. is presenting the newest data concerning its leading pre-clinical therapeutic, ORP-100, at the 28th Annual North American Cystic Fibrosis Conference held October 9-11 in Atlanta. ORP-100 is being developed to treat cystic fibrosis by attacking the pathological, adhesive mucus found in patients’ lungs. According to a…

CF Patient Lung Function Higher in US than in UK

Young adults and children with cystic fibrosis in the United States have better lung function than those who live in the United Kingdom, despite the fact that both countries have well-developed healthcare systems. Differences in lung function may be a result of differences in healthcare structure, according to the…

Cystic Fibrosis Therapy Lynovex Granted Orphan Drug Status

Drug development companies such as NovaBiotics that are devoted to designing and developing treatments for patients with difficult-to-treat, medically unmet diseases are often faced with the hurdle of recruiting enough patients to conduct the clinical trials necessary to approve new treatments. Recently, the hindrance has…

Unmet Patient Needs in CF Highlighted by Atlantis Healthcare Report

Cystic fibrosis is among the numerous chronic conditions categorized as rare diseases. As many cystic fibrosis patients know, a unique set of burdens are placed upon themselves and their caregivers, and Atlantis Healthcare is working to bring light to patients’ hardships. Recently, Atlantis Healthcare released a white paper with…